Enclomiphene vs tamoxifen: which SERM actually fits your goal

Last updated 2026-07-27

What is the actual difference between enclomiphene and tamoxifen?

Both drugs are selective estrogen receptor modulators (SERMs). They block estrogen's negative feedback signal at the hypothalamus, which tricks your brain into thinking estrogen is low. That triggers more GnRH, more LH and FSH, and more endogenous testosterone production from the testes. The mechanism is genuinely similar. The difference is what each molecule was built for and what regulatory history it actually has. Tamoxifen (brand name Nolvadex) was approved by the FDA in 1977 for breast cancer treatment and prevention in high-risk women ^[1]. It's a triphenylethylene SERM with tissue-selective activity: it blocks estrogen receptors in breast tissue while acting as a partial agonist elsewhere (bone, uterus). Its use for male hypogonadism or fertility is entirely off-label. Enclomiphene is one of the two isomers that make up clomiphene citrate. Clomiphene itself is FDA-approved, but only for female ovulation induction (brand name Clomid), not for men ^[2]. Enclomiphene was developed separately as a single-isomer drug (the Androxal program, run by Repros Therapeutics) specifically to raise testosterone in men with secondary hypogonadism while preserving sperm production. That program never reached FDA approval despite multiple Phase 3 trials in the 2010s ^[3]. Today, enclomiphene sold in the US is compounded by 503A or 503B pharmacies, not manufactured as an approved drug product. So the practical distinction: tamoxifen has an FDA-approved indication, just not this one. Enclomiphene has no FDA-approved indication at all, in any form, for any population.

Is enclomiphene the same thing as clomiphene?

No, and this trips people up constantly. Clomiphene citrate is a 50/50 (roughly) mixture of two isomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer) ^[4]. When men take generic Clomid off-label for low testosterone, they're taking both isomers together. Enclomiphene is the isolated trans-isomer only. It's a shorter-acting, more potent estrogen receptor antagonist at the hypothalamus. Zuclomiphene, the isomer left out of enclomiphene, has a much longer half-life (estimated in weeks) and behaves more like a weak estrogen agonist in some tissues, which some researchers believe contributes to the visual side effects and mood complaints associated with clomiphene use ^[5]. The theoretical appeal of enclomiphene over plain clomiphene is that you get the LH/FSH-driving antagonist effect without as much zuclomiphene accumulation. Whether that translates into a measurably better side effect profile in practice is not settled by large head-to-head trials. It's a plausible, mechanistically supported idea, not a proven clinical outcome.

Does enclomiphene or tamoxifen preserve fertility better?

Both preserve the fertility axis better than exogenous testosterone, and that's the central reason men look at either drug instead of TRT. Exogenous testosterone shuts down the hypothalamic-pituitary-gonadal (HPG) axis: your brain sees plenty of testosterone-like signal, stops sending LH and FSH, and the testes stop producing sperm and can shrink. Both enclomiphene and tamoxifen work by the opposite mechanism, raising LH and FSH, so testicular function and sperm production are generally maintained or increased rather than suppressed. For tamoxifen specifically, a randomized controlled trial in men with idiopathic infertility found that tamoxifen citrate improved sperm concentration and pregnancy rates compared to placebo, though effect sizes were modest and study quality in this literature is generally rated low to moderate ^[6]. It's also used clinically to help restart natural testosterone and spermatogenesis after anabolic steroid use, sometimes as part of post-cycle therapy protocols, though this is off-label and not FDA-studied for that purpose. For enclomiphene, published trial data (from the Androxal program and independent research) shows it raises testosterone into normal range in most hypogonadal men while maintaining sperm counts, in contrast to testosterone replacement, which reliably suppresses them ^[7]. A frequently cited finding from the Phase 3 program: enclomiphene increased LH, FSH, and total testosterone while sperm counts were preserved, whereas the testosterone gel comparator group showed suppressed LH/FSH and reduced sperm counts ^[3]. Neither drug is FDA-studied or approved specifically to treat male infertility or to guarantee pregnancy outcomes. If fertility preservation is your priority, the honest framing is: both drugs are the right class of tool, mechanistically, compared to TRT, but neither comes with a guarantee, and semen parameters (not live birth rates) are what most of the data actually measures.

How do the side effects compare?

Here's a side-by-side of what's reported in the literature and clinical experience for each drug, at typical off-label doses used in men. | Side effect category | Enclomiphene | Tamoxifen |

Which one is FDA-approved, and does that matter for men using it?

Tamoxifen is FDA-approved, but only for breast cancer treatment and risk reduction in women ^[1]. Enclomiphene has no FDA approval in any form or population. Both uses in men, for testosterone or fertility support, are off-label or, for enclomiphene, entirely outside the approved drug supply chain. This matters practically in a few ways. An FDA-approved drug like tamoxifen has a fixed, tested formulation, a known bioequivalence standard, and a manufacturer accountable to the FDA for quality control under 21 CFR Part 211 ^[9]. When your doctor prescribes tamoxifen off-label for male fertility, the pill itself went through the same manufacturing scrutiny as the on-label breast cancer version. Enclomiphene, since the Repros Androxal program never completed FDA review, does not exist as an FDA-approved product in the US. What you can get is compounded enclomiphene, made by a 503A pharmacy (patient-specific compounding) or 503B outsourcing facility (batch production under closer FDA oversight, per Section 503B of the FD&C Act ). Compounded drugs are not FDA-approved and do not go through the same premarket efficacy and safety review; 503B facilities do register with FDA and follow current good manufacturing practice requirements, which is a meaningfully higher bar than an unregulated compounding pharmacy, but it's still not the same as an approved New Drug Application. If regulatory status and quality assurance matter to you, that's a real difference, and it's the honest answer to why some men default to tamoxifen (approved molecule, off-label use) instead of enclomiphene (unapproved molecule, compounded only). If you go the enclomiphene route anyway, because you want the more targeted single-isomer profile, using a provider-reviewed source that's transparent about its 503A/503B pharmacy partner is the more responsible way to do it, since it at least keeps you within a regulated compounding framework rather than an anonymous overseas supplier.

What does the dosing look like for each?

Typical off-label enclomiphene protocols for men run 12.5mg to 25mg daily, sometimes dosed every other day, based on the Phase 3 Androxal trial doses and current compounding pharmacy practice ^[3]. Tamoxifen for male hypogonadism or fertility is usually dosed at 10mg to 20mg daily, based on doses used in the male infertility RCT literature ^[6]. Neither has an FDA-approved male dosing label, so these numbers come from trial protocols and off-label clinical practice, not an approved package insert. If you're starting enclomiphene, working from an actual dosage guide and a dosage calculator that reflects real trial dosing ranges is a better starting point than guessing from forum posts.

Can you combine enclomiphene and tamoxifen, or switch between them?

Some off-label protocols, particularly post-cycle therapy regimens used by anabolic steroid users, do combine a SERM with other compounds, but there's no controlled trial data showing enclomiphene plus tamoxifen together outperforms either alone in hypogonadal men. Combining two SERMs that act on the same receptor pathway has an unclear rationale and adds side effect risk without demonstrated added benefit. Switching from one to the other is more common and more defensible; if a man doesn't tolerate tamoxifen's mood or visual side effects, a trial of enclomiphene (or vice versa) is a reasonable clinical decision, since the mechanisms overlap but the specific molecule and metabolite profile differ. This should be a decision made with a prescriber tracking labs (LH, FSH, total and free testosterone, estradiol) before and after the switch, not a self-directed swap.

How do enclomiphene and tamoxifen compare to just doing TRT?

This is really the question underneath the whole comparison. TRT (testosterone injections, gels, or pellets) reliably raises testosterone levels, often more predictably and to a higher level than either SERM. But it does so by replacing the signal rather than restoring it, which suppresses LH and FSH and, with it, sperm production and often testicular volume ^[7]. Enclomiphene and tamoxifen both raise testosterone by increasing the body's own LH and FSH output, so the testes keep making testosterone and sperm rather than being told to stand down. For a man who wants to preserve fertility, whether he's actively trying to conceive now or just doesn't want testicular atrophy and wants to keep the option open, that mechanism difference is the whole reason SERMs come up as an alternative to TRT at all. The honest tradeoff: TRT has a much larger, longer safety and efficacy database and is FDA-approved for diagnosed hypogonadism. Neither SERM is FDA-approved for this use. Testosterone levels on SERMs are also generally more modest than what injectable TRT can achieve, and men with primary testicular failure (as opposed to secondary/hypothalamic-pituitary hypogonadism) won't respond to a SERM at all, because the problem isn't insufficient LH/FSH signal, it's testes that can't respond to it.

What do the clinical trials actually show for enclomiphene?

The most cited data comes from Repros Therapeutics' Phase 3 program for Androxal (enclomiphene citrate), which compared enclomiphene to placebo and to topical testosterone gel in men with secondary hypogonadism. Across these trials, enclomiphene raised total testosterone into the normal range in the large majority of treated men while maintaining LH, FSH, and sperm counts, in contrast to the testosterone gel arm, which suppressed LH, FSH, and sperm parameters ^[3]. Despite completing Phase 3 trials, Repros withdrew or did not pursue FDA approval to completion, and the drug was never brought to market as an approved product; the company's public filings and subsequent lack of an approved NDA are the basis for saying enclomiphene 'never reached FDA approval' as a standalone drug . Since then, independent academic studies and smaller trials have continued to study enclomiphene, generally replicating the testosterone-raising, LH/FSH-preserving pattern, but there is no FDA-reviewed efficacy and safety package equivalent to what tamoxifen has from its oncology approval history.

What does the clinical evidence show for tamoxifen in men?

Tamoxifen's approval evidence is all in women with breast cancer. The male-specific data is a separate, smaller body of off-label research, mostly in male infertility and hypogonadism. A randomized trial published in the male infertility literature found tamoxifen citrate improved sperm parameters and pregnancy rates over placebo in men with idiopathic oligospermia, though the trial size and overall evidence quality are limited ^[6]. A systematic look at SERMs (clomiphene and tamoxifen) for idiopathic male infertility, reviewed in the urology and endocrinology literature, generally concludes that these drugs can raise testosterone and improve some semen parameters, but the quality of evidence for actual pregnancy and live birth outcomes remains low, and professional guidelines stop short of strongly endorsing SERMs as first-line infertility treatment for this reason . That's a fair summary for enclomiphene too: semen parameter improvement has real support, live birth guarantees do not.

FAQs

Frequently asked questions

Is enclomiphene the same as tamoxifen?

No. Both are SERMs that raise LH, FSH, and testosterone by blocking estrogen feedback at the hypothalamus, but they're different molecules. Tamoxifen is FDA-approved for breast cancer; enclomiphene is an isolated isomer of clomiphene, developed for male hypogonadism, that never received FDA approval and is only available compounded.

Is enclomiphene the same as clomiphene (Clomid)?

No. Clomiphene citrate is a mixture of two isomers, enclomiphene and zuclomiphene. Enclomiphene is the isolated trans-isomer, thought to drive most of the LH/FSH-raising effect, while zuclomiphene has a much longer half-life and is associated with more of the estrogen-agonist-like side effects some men report on generic clomiphene.

Is enclomiphene FDA-approved?

No. Enclomiphene (developed as Androxal by Repros Therapeutics) completed Phase 3 trials but never reached FDA approval as a standalone drug. What's sold today in the US is compounded by 503A or 503B pharmacies, not manufactured as an approved drug product, so it doesn't have an FDA-reviewed label.

Does tamoxifen preserve fertility better than TRT?

Yes, mechanistically. Tamoxifen raises LH and FSH rather than replacing testosterone, so it tends to preserve or improve sperm production, unlike TRT, which suppresses the HPG axis and sperm counts. A randomized trial found tamoxifen improved sperm concentration and pregnancy rates over placebo in men with idiopathic infertility, though effect sizes were modest.

Can I take enclomiphene and tamoxifen together?

There's no solid trial data showing that combining them outperforms either alone, and both act on overlapping estrogen-receptor pathways, so the added benefit is unclear while side effect risk could increase. If one isn't working or isn't tolerated, switching under a prescriber's guidance is a more evidence-based move than stacking.

Why did enclomiphene never get FDA approved?

Repros Therapeutics completed Phase 3 trials for enclomiphene (as Androxal) showing it raised testosterone while preserving sperm counts, but the company did not carry the drug to a completed, approved New Drug Application. The exact commercial and regulatory reasons weren't fully public, but the practical result is that enclomiphene has no FDA-approved product today.

Does enclomiphene shrink your testicles like TRT does?

No, not by the same mechanism. TRT suppresses LH and FSH, which drives testicular shrinkage. Enclomiphene increases LH and FSH, so testicular volume and function are generally maintained or can increase, based on trial data comparing it to testosterone gel, though this isn't a guarantee for every individual.

What's the difference between 503A and 503B compounded enclomiphene?

503A pharmacies compound patient-specific prescriptions under less centralized FDA oversight; 503B outsourcing facilities produce in batches, register with the FDA, and follow current good manufacturing practice standards under Section 503B of the FD&C Act. Neither is the same as an FDA-approved manufactured drug, but 503B carries closer federal quality oversight.

What are the main side effects of tamoxifen in men?

Reported side effects include mood changes, visual disturbances (rare but linked to retinopathy with prolonged high-dose use), and liver enzyme changes. Tamoxifen also carries an FDA boxed warning for uterine cancer, stroke, and blood clots, though that warning is based on data in women; male-specific long-term risk data is limited.

Which is cheaper, enclomiphene or tamoxifen?

Generic tamoxifen is widely manufactured and typically inexpensive at retail pharmacies since it's an approved generic drug. Compounded enclomiphene pricing varies by pharmacy and dose, and since it's not mass-manufactured as an approved generic, it's generally priced more like a specialty compounded product than a commodity generic.

Can women take enclomiphene or is it only for men?

Enclomiphene has been studied almost exclusively in men for testosterone and fertility support. Tamoxifen is FDA-approved for use in women, for breast cancer treatment and risk reduction, and is not used for fertility support in women in the way clomiphene is for ovulation induction.

Do I need blood monitoring on enclomiphene or tamoxifen?

Yes, for either. Prescribers typically check baseline and follow-up total and free testosterone, LH, FSH, and estradiol, and may monitor liver enzymes. Tamoxifen labeling also recommends periodic eye exams with extended use, given rare associations with visual changes. Neither drug should be run without lab follow-up.

Sources

1. Wiehle et al., Journal of Sexual Medicine, enclomiphene Phase 3 data: Enclomiphene raised testosterone while preserving LH, FSH, and sperm counts compared to testosterone gel in Phase 3 trials
2. NIH PubChem, Clomiphene compound summary: Clomiphene citrate is a mixture of enclomiphene (trans) and zuclomiphene (cis) isomers
3. Kim et al., Translational Andrology and Urology, review of clomiphene isomers: Zuclomiphene has a longer half-life and different receptor activity than enclomiphene, relevant to side effect differences
4. Adamopoulos et al., Fertility and Sterility, tamoxifen RCT in male infertility: Tamoxifen citrate improved sperm concentration and pregnancy rates versus placebo in men with idiopathic infertility
5. Wiehle et al., BJU International, enclomiphene vs testosterone gel: Testosterone gel suppressed LH, FSH, and sperm counts while enclomiphene preserved them
6. FDA, 21 CFR Part 211 current good manufacturing practice: FDA-approved drug manufacturers must follow current good manufacturing practice regulations
7. FDA, Section 503B outsourcing facilities: 503B outsourcing facilities register with FDA and compound under closer oversight than traditional 503A pharmacies
8. SEC EDGAR, Repros Therapeutics filings on Androxal (enclomiphene) NDA status: Repros Therapeutics completed Phase 3 trials for enclomiphene but the drug never reached a completed FDA-approved New Drug Application
9. Chua et al., Andrology, systematic review of SERMs for male infertility: Evidence for SERMs like clomiphene and tamoxifen improving pregnancy and live birth outcomes in male infertility is low quality despite improvements in some semen parameters